A multicenter, non-interventional, descriptive study to assess assay concordance of HER2 IHC testing in Chinese pan-tumor patients

Trial Identifier: D9673L00020
Sponsor: AstraZeneca
Start Date: March 2026
Primary Completion Date: December 2026
Study Completion Date: December 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Chengdu, China
China Haerbin, China
China Jinan, China
China Nantong, China
China Shanghai, China
China Shenyang, China
China Wulumuqi, China